News

Seralutinib (GB002), an investigational inhaled treatment for pulmonary arterial hypertension (PAH), effectively treated severe disease in two animal models, a study demonstrated. Further, when compared directly, inhaled seralutinib showed greater efficacy than imatinib, an approved cancer therapy also being investigated for PAH. Gossamer Bio, seralutinib’s developer, now is testing…

Treatment with cannabidiol (CBD) reduced inflammation and lessened damaging oxidative stress in a rat model of pulmonary hypertension (PH), a new study reports. “The promising results of our research may form the basis for a more detailed study of the effects of CBD or its derivatives on PH, especially…

Despite recent advances in care, mortality while in the intensive care unit (ICU) and up to one year thereafter remains high among people with pulmonary arterial hypertension (PAH), a new study reports. Risk factors for mortality one year after ICU discharge included low blood sodium, raised pro-B-type natriuretic peptide…

High scores on a measure known as H2FPEF — which reflect an increased probability of dysfunction of the left ventricle (LV) of the heart — were associated with signs of LV impairment and a worse prognosis in patients with idiopathic pulmonary arterial hypertension (IPAH), a study found. Patients with…

Sacubitril-valsartan — a combination oral therapy approved to treat heart failure — rapidly reduces pulmonary blood pressure in people with pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (HFpEF), according to data from a Phase 3 clinical trial. Notably, these benefits were accompanied by reduced lung…

People with pulmonary hypertension (PH) who were diagnosed with COVID-19 had a high rate of hospitalization and in-hospital mortality, a French study concluded. Risk factors for adverse outcomes included being older, male, having co-existing conditions, or comorbidities, and having more severe PH. Anticoagulants (blood thinners) were the only treatment…

A mean pulmonary artery pressure (mPAP) — blood pressure in the lungs — of less than 40 mmHg (millimeters of mercury) significantly increases the survival rate of patients with different subsets of pulmonary arterial hypertension (PAH), a study suggests. The successful outcome was achieved with an intensive therapeutic approach…

Anumana’s electrocardiogram (ECG)-based algorithm for the early detection of pulmonary hypertension (PH) has been designated a breakthrough device by the U.S. Food and Drug Administration (FDA). Developed through a collaboration of scientists at Anumana, Janssen Research and Development, and the Mayo Clinic, the artificial intelligence (AI)-powered algorithm is designed…

The U.S. Food and Drug Administration (FDA) has approved Tyvaso DPI, a dry powder, inhaled formulation of treprostinil, to improve exercise ability in people with pulmonary arterial hypertension (PAH) or pulmonary hypertension associated with interstitial lung disease (PH-ILD). Tyvaso DPI is now the only dry powder inhaler approved…

Sacubitril/valsartan, a fixed-dose combination oral therapy approved for heart failure, was found to improve right heart function and lower pulmonary blood pressure, according to a new pooled analysis of multiple studies. This meta-analysis supports a new therapeutic role for sacubitril/valsartan for people with pulmonary hypertension (PH) associated with heart…

Even with modern advances in treatments, many people in the U.S. with pulmonary arterial hypertension (PAH) are at an “unacceptably high” risk of mortality, a new study shows. The study, “Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry,” was…

Aerovate Therapeutics‘ AV-101, an inhaled formulation of imatinib for treating pulmonary arterial hypertension (PAH), was well tolerated in healthy adult volunteers enrolled in a Phase 1 trial. Study data also indicate AV-101, which delivers the medication directly to the lungs, reduced its systemic (whole body) exposure. This is…